Public Release: 

Clinical trial evaluates heterologous prime/boost regimens in preventative HIV vaccination

JCI Journals

Almost 40 million people worldwide live with HIV/AIDS, with an estimated 2.5 million new cases per year. Therefore, there has been a large global effort to develop an effective vaccine against the virus. HIV-1 vaccine development has been challenging but recent clinical trials have been promising. A new study in the Journal of Clinical Investigation discusses the results from a clinical trial that evaluated the immune response following different HIV vaccine regimes. Nicole Frahm and colleagues tested prime-boost regimes combining a New York vaccinia HIV clade B (NYVAC-B) vaccine and a recombinant adenovirus 5-vectored (rAd5-vectored) vaccine in a cohort of healthy volunteers. Individuals that received the rAd5-vectored vaccine followed by the NYVAC-B vaccine exhibited the strongest anti-HIV immune responses. A regime in which individuals received the NYVAC-B vaccine prior to the rAd5-vectored vaccine was not as effective. The results from this study will be important for the design of further clinical trials to evaluate potential HIV-1 vaccine regimes.

###

TITLE: HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

AUTHOR CONTACT: Nicole Frahm
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Phone: 206.667.6268; Fax: 206.667.6136; E-mail: nfrahm@fhcrc.org

View this article at: http://www.jci.org/articles/view/75894?key=30bb5f40d024b357fffa

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.